Jade Biosciences, Inc.

Jade Biosciences, Inc. (JBIO)

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

Market Cap

$315M

Revenue

$0

P/E Ratio

N/A

P/B Ratio

-9.91

D/E Ratio

-2.30

Dividend Yield

0.00%

PEG Ratio

0.00

Net Income

-$94K

Net Profit Margin

0.00%

Beta

0.9249

Gross Margin

0.00%

R/S Growth

0.00

52W Low

$0.00

52W High

$0.00

Updated: June 30 at 18:24:03